​

Enlivex Therapeutics (ENLV) Stock Forecast, Price Target & Predictions

OverviewOwnershipChart

ENLV Stock Forecast

Enlivex Therapeutics (ENLV) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $15.00, with a high of $15.00 and a low of $15.00. This represents a 1495.74% increase from the last price of $0.94.

- $3 $6 $9 $12 $15 High: $15 Avg: $15 Low: $15 Last Closed Price: $0.94

ENLV Stock Rating

Enlivex Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

ENLV Price Target Upside V Benchmarks

TypeNameUpside
StockEnlivex Therapeutics1495.74%
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.94$0.94$0.94
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2511---2
May, 2511---2
Apr, 2511---2
Mar, 2511---2
Feb, 2511---2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 02, 2022H.C. Wainwright$15.00$5.69163.62%1495.74%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 27, 2024EF HuttonBuyinitialise
Jun 11, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.56-----
Avg Forecast$-1.36$-0.65$-0.58$-0.59$-0.78$-0.94
High Forecast$-1.36$-0.65$-0.58$-0.59$-0.78$-0.94
Low Forecast$-1.36$-0.65$-0.58$-0.59$-0.78$-0.94
Surprise %14.71%-----

Revenue Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast------
High Forecast------
Low Forecast------
Surprise %------

Net Income Forecast

$-30M $-26M $-22M $-18M $-14M $-10M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-29.07M-----
Avg Forecast$-25.26M$-12.07M$-10.77M$-10.96M$-14.49M$-17.46M
High Forecast$-25.26M$-12.07M$-10.77M$-10.96M$-14.49M$-17.46M
Low Forecast$-25.26M$-12.07M$-10.77M$-10.96M$-14.49M$-17.46M
Surprise %15.07%-----

ENLV Forecast FAQ

Is Enlivex Therapeutics stock a buy?

Enlivex Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Enlivex Therapeutics is a favorable investment for most analysts.

What is Enlivex Therapeutics's price target?

Enlivex Therapeutics's price target, set by 4 Wall Street analysts, averages $15 over the next 12 months. The price target range spans from $15 at the low end to $15 at the high end, suggesting a potential 1495.74% change from the previous closing price of $0.94.

How does Enlivex Therapeutics stock forecast compare to its benchmarks?

Enlivex Therapeutics's stock forecast shows a 1495.74% upside, outperforming the average forecast for the healthcare stocks sector (23.68%) and outperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Enlivex Therapeutics over the past three months?

  • June 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Enlivex Therapeutics’s EPS forecast?

Enlivex Therapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.65, marking a -58.33% decrease from the reported $-1.56 in 2023. Estimates for the following years are $-0.58 in 2025, $-0.59 in 2026, $-0.78 in 2027, and $-0.94 in 2028.

What is Enlivex Therapeutics’s revenue forecast?

Enlivex Therapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $0, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $0, followed by $0 for 2026, $0 for 2027, and $0 for 2028.

What is Enlivex Therapeutics’s net income forecast?

Enlivex Therapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-12.073M, representing a -58.46% decrease from the reported $-29.068M in 2023. Projections indicate $-10.773M in 2025, $-10.959M in 2026, $-14.488M in 2027, and $-17.46M in 2028.